The race for the next Ozempic | Wired
Excerpt from Wired: “The next wave of obesity drugs could help people lose even more weight—and make some pharma companies a fortune. In the 1980s, researchers identified a hormone in the human gut called GLP-1 that triggers the release of insulin, which controls blood sugar levels. The discovery would eventually launch a new class of diabetes drugs known as GLP-1 receptor agonists, the first of which was approved in 2005…” Read more.
Biogen and Sage to scrap neurological disorder drug development after trial failure | Reuters
Excerpt from Reuters: “Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday. The setback is the latest after Sage and partner Biogen’s pill, Zurzuvae, could not secure the U.S. health regulator’s nod for treating clinical depression, a much larger market, while it was approved as a treatment for postpartum depression.” Read more.
Pharma aims to deliver personalized cancer therapies more quickly | Reuters
Excerpt from Reuters: “Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient’s disease course.” Read more.
Sorry, the comment form is closed at this time.